flizasertib

An orally available inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1; receptor-interacting protein 1; RIP1) with potential immunomodulatory and anti-inflammatory activities. Upon oral administration, flizasertib inhibits RIP1-mediated signaling, which may preserve intestinal stem cells (ISCs) and prevent RIP1-mediated gastrointestinal (GI) damage in acute graft-versus-host disease (GvHD). RIP1 plays a key role in inflammation and cell death in response to tissue damage and pathogen recognition.